Scleroderma Foundation increases research funding by more than 100%

By Jenni Spinner contact

- Last updated on GMT

(Aneese/iStock via Getty Images)
(Aneese/iStock via Getty Images)

Related tags: Immune system, Rare disease, preclinical, Research

The organization, focused on building awareness and finding therapies for the rare disease, is boosting its annual research funding to more than $2.7m USD.

In alignment with the June 29 commemoration of World Scleroderma Day, the Scleroderma Foundation announced it has increased its peer-reviewed scientific research funding to $2.723m USD each year. In addition, the group is increasing the amount of its individual awards to $200,000.

The changes are effective for the upcoming 2022 grant funding cycle, with a proposal submission deadline extended from September 15 to September 30. The increase includes specific requests for proposals covering two key areas

  • scleroderma-related lung disease research
  • pediatric scleroderma

According to the foundation, a specific, donor-funded grant of $200,000 is expected to be awarded to an established investigator conducting scleroderma-related lung disease research.  Pediatric-scleroderma research is earmarked for up to $500,000 in awards and is open to submissions from new and established investigators.

Robert Riggs, CEO of the Scleroderma Foundation, said the group’s efforts to fund research, even in the face of economic hardship, is essential to pursue treatment of the rare disease.

The need to accelerate the pace of discovery in scleroderma research is urgent​," Riggs commented. “We are proud of our leadership role in advancing scientific discovery and doing so with the integrity of the peer-review process​."

The group’s Peer-Review Research Committee is made up of medical and research experts from across the US. According to the Scleroderma Foundation, the committee utilizes the same merit-based scoring system as the one used by the National Institutes of Health.

Scleroderma is a rare disease that impacts the human body’s connective tissue as well as the vascular system. Typically considered an autoimmune rheumatic disease, the disease causes an overproduction of collagen, or fibrosis, that hardens tissue and damages organs.  Commonly affecting the skin, scleroderma also affects internal organs; to date, researchers do not know the cause, and currently there are no approved treatments or cures.

Related news

Show more

Related products

show more

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

Related suppliers

Follow us


View more